- Home
- NXTC vs MIRA Comparison
NXTC vs MIRA Comparison
Compare NXTC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- MIRA
- Stock Information
- Founded
- NXTC 2015
- MIRA 2020
- Country
- NXTC United States
- MIRA United States
- Employees
- NXTC N/A
- MIRA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- MIRA Health Care
- Exchange
- NXTC Nasdaq
- MIRA Nasdaq
- Market Cap
- NXTC 21.6M
- MIRA 18.4M
- IPO Year
- NXTC 2019
- MIRA 2023
- Fundamental
- Price
- NXTC $0.72
- MIRA $1.10
- Analyst Decision
- NXTC Strong Buy
- MIRA Strong Buy
- Analyst Count
- NXTC 2
- MIRA 2
- Target Price
- NXTC $4.00
- MIRA $14.00
- AVG Volume (30 Days)
- NXTC 61.8K
- MIRA 223.3K
- Earning Date
- NXTC 03-20-2025
- MIRA 03-31-2025
- Dividend Yield
- NXTC N/A
- MIRA N/A
- EPS Growth
- NXTC N/A
- MIRA N/A
- EPS
- NXTC N/A
- MIRA N/A
- Revenue
- NXTC N/A
- MIRA N/A
- Revenue This Year
- NXTC N/A
- MIRA N/A
- Revenue Next Year
- NXTC N/A
- MIRA N/A
- P/E Ratio
- NXTC N/A
- MIRA N/A
- Revenue Growth
- NXTC N/A
- MIRA N/A
- 52 Week Low
- NXTC $0.66
- MIRA $0.51
- 52 Week High
- NXTC $2.57
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- NXTC 40.34
- MIRA 43.36
- Support Level
- NXTC $0.66
- MIRA $1.09
- Resistance Level
- NXTC $0.79
- MIRA $1.18
- Average True Range (ATR)
- NXTC 0.06
- MIRA 0.06
- MACD
- NXTC 0.00
- MIRA -0.00
- Stochastic Oscillator
- NXTC 42.21
- MIRA 7.69
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.